Here, we outline a novel BCMA-targeting ADC, STI-8811, which binds BCMA with unique fast-on/fast-off binding that maintains specific and efficient internalization into BCMA-expressing multiple myeloma cell lines, resulting in effective tumor eradication both in vitro and in vivo. Here, TNFRSF17 is linked to plasma cell myeloma.